reports
Update to Medium-Term Financial Guidance and 2023 Trading and Notice o...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmesFY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim ResultsFY2023 Preliminary Results to be reported on Mon...
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and...
Oxford Biomedica is hosting a free webinar to share clients’ success s...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable techni...
- Martin Hall
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
Business Update
Business Update Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On track to achieve 2023 guidance provided at the Interim Results and reiteration of medium term guidance; growth supported by new orders recently signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectorsProgress towards multi-vector multi-site model with transfer of lentiviral vector capabilities to Bedford, Massachusetts site and acquisition of ABL EuropeRecru...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut M...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe The transaction Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UKExpands Oxford Biomedica’s capacity in proce...
Oxford BioMedica: 1 director
A director at Oxford BioMedica bought 12,000 shares at 294p and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Oxford Biomedica and Institut Mérieux enter into exclusive negotiation...
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered ...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUN...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023 The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023 Newly appointed Chief Exe...
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
Oxford Biomedica to host webinar showcasing the TetraVecta™ system Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by Dr Nick Clarkson, Vice Presid...
Oxford Biomedica launches TetraVecta - the next generation lentiviral ...
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system Oxford Biomedica launches TetraVectaTM - the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral vectors, while incorporating new and enhanced safety f...
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within i...
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford BiomedicaStuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director Oxford, UK – 20 February 2023: Oxford, UK – Oxford Biomedica (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer (CEO...
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer Oxford, UK – 22 November 2022: Oxford Bi...
Oxford Biomedica to complete sale and leaseback of Windrush Court faci...
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale of its Windrush Court facility (the "Property") to Kadans Science Partner (“Kadans”) for £60 million. Completion is due to occur on or around the 18th November 2022. The sale proceeds of £60 million exceed the target offer ...
Amendment of Short-Term Loan Facility into new Term Loan Facility With...
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree Partial repayment and ...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE ...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A GLOBAL VIRAL VECTOR LEADER Oxford, UK – 15 September 2022: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2022. Roch Doliveux, Oxford Biomedica’s Chair and Interim Chief Executive Officer, said: “We have made significant strategic and operational prog...
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for...
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. The LSA grants the new partner a non-exclusive...
Oxford Biomedica initiates new project with Orchard Therapeutics utili...
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform will be used to develop a producer cell line c...
Oxford Biomedica Preliminary Results
Oxford Biomedica Preliminary Results Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I am delighted with our performance in 2021 which was a true testament to the hard work of all our employees. 2021 financial performance was exceptional due to larg...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.